Please provide your email address to receive an email when new articles are posted on . The safety and efficacy of selective laser trabeculoplasty was comparable to argon laser trabeculoplasty. Data ...
Please provide your email address to receive an email when new articles are posted on . Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and ...
CHICAGO -- Upfront laser trabeculoplasty significantly slowed glaucoma progression and vision loss as compared with eye drops, long-term follow-up from a large randomized trial showed. After 6 years ...
Glaucoma is a lifelong eye disease that requires regular treatment. For many, it can be controlled by a daily eye drop regimen, but the treatment is not perfect—the preservatives in the drops can ...
Nate Lighthizer, OD, FAAO, discusses laser therapy and how attendees at Southeastern Educational Congress of Optometry (SECO) 2025 got hands-on experience at the conference. Laser therapy has been ...
ViaLase, the California developer of laser-based glaucoma treatment, has announced that the first patient has been treated in its US Investigational Device Exemption (IDE) clinical trial. The trial is ...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care, dedicated to helping people see brilliantly, announced today the full U.S. commercial availability of Voyager™ DSLT, the ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results